

10. The compound as claimed in anyone of the claims 1 to 8 for the use in a A method of inhibiting the replication of an RNA-containing virus, ~~comprising contacting said virus with a therapeutically effective amount of a compound or combination of compounds according to any one of claims 1-8, or a pharmaceutically acceptable salt thereof.~~
11. The compound as claimed in any one of the claims 1 to 8 for the use in a A method of treating or preventing infection caused by an RNA-containing virus, ~~comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound or combination of compounds according to any one of claims 1-8, or a pharmaceutically acceptable salt thereof.~~
12. The compound for use in a method The method of claim 11, wherein the RNA-containing virus is hepatitis C virus.
13. The compound for use in a method The method of claim 11, further comprising the step of co-administering one or more agents selected from a host immune modulator and an antiviral agent, or a combination thereof.
14. The compound for use in a The method of claim 13, wherein the host immune modulator is selected from interferon-alpha, pegylated-interferon-alpha, interferon-beta, interferon-gamma, consensus interferon, a cytokine, and a vaccine.
15. The compound for use in a The method of claim 13, wherein the antiviral agent inhibits replication of HCV by inhibiting a host cellular function associated with viral replication.
16. The compound for use in a The method of claim 13, wherein the antiviral agent inhibits the replication of HCV by targeting a protein of the viral genome.
17. The compound use in a The method of claim 13, wherein said antiviral agent is an inhibitor of a HCV viral protein, a replication process, or a combination thereof, wherein said targeting protein or replication process is selected from helicase, protease, polymerase, metalloprotease, NS4A, NS4B, NS5A, assembly, entry, and IRES.

- 18. The compound use in a** The method of claim 13, further comprising the step of co-administering an agent or combination of agents that treat or alleviate symptoms of HCV infection selected from cirrhosis and inflammation of the liver.

19. The compound for use in a The method of claim 13, further comprising the step of co-administering one or more agents that treat patients for disease caused by hepatitis B (HBV) infection.
20. The compound for use in a The method of claim 13, further comprising the step of co-administering one or more agents that treat patients for disease caused by human immunodeficiency virus (HIV) infection.
21. The pharmaceutical composition of claim 9, further comprising an agent selected from interferon, pegylated interferon, ribavirin, amantadine, an HCV protease inhibitor, an HCV polymerase inhibitor, an HCV helicase inhibitor, or an internal ribosome entry site inhibitor.
22. The composition of claim 9, further comprising a cytochrome P450 monooxygenase inhibitor or a pharmaceutically acceptable salt thereof.
23. The compound for use in a A method of treating hepatitis C infection in a subject in need thereof comprising co-administering to said subject a cytochrome P450 monooxygenase inhibitor or a pharmaceutically acceptable salt thereof, and a compound of any one of claims 1-8 or a pharmaceutically acceptable salt thereof.
24. The compound according to any one of claims 1-8, or a pharmaceutically acceptable salt thereof, for use in treating or preventing an infection in a patient caused by an RNA-containing virus.